Advertisement

Immunogenicity of poliovirus vaccines with special reference to the choice between oral and inactivated vaccines in developing countries

  • B. D. Schoub

Summary

Both inactivated and oral poliovirus vaccines have successfully eradicated poliomyelitis in the developed world. Inactivated vaccine may appear to have some advantages for the developing world, particularly with regard to interference and greater stability, but fails to address the major reservoir of faecal-orally spread virus, the gastrointestinal tract. Inactivated vaccine used to supplement oral vaccine schedules increases cost and could cause confusion in adminis tration. Interference in oral vaccine schedules could be addressed by a supplementary neonatal dose. In most of Africa, type 1 poliovirus is the dominant endemic strain and also the cause of outbreaks, and neonatal supplementation with type 1 would have particular advantages.

Keywords

Vaccine Coverage Oral Poliovirus Vaccine Population Immunity Inactivate Poliovirus Vaccine Paralytic Poliomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kok PW, Leeuwenburg J, Tukei P, van Wezel AL, Kapsenberg JG, van Steenis G, Galazka A, Robertson SE, Robinson D (1992) Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bull WHO 70:93–103PubMedGoogle Scholar
  2. 2.
    Johnson S, Schoub BD, McAnerney JM, Gear JSS, Moodie JM, Garrity SL, Klaassen KIM ,Küstner HGV (1984) Poliomyelitis outbreak in South Africa ,1982. II. Laboratory and vaccine aspects. Trans R Soc Trop Med Hyg 78: 26–31PubMedCrossRefGoogle Scholar
  3. 3.
    Schoub BD, Johnson S, McAnerney JM, Küstner HGV, van der Merwe GA (1986) A comprehensive investigation of immunity to poliomyelitis in a developing country. Am J Epidemiol 123: 316–324PubMedGoogle Scholar
  4. 4.
    Schoub BD, Johnson S, McAnerney JM, van Middelkoop A, Küstner HGV, Windsor I, Vinsen C, McDonald K (1992) Poliomyelitis outbreak in Natal/KwaZulu, South Africa, 1987–1988. 2. Immunity aspects. Trans R Soc Trop Med Hyg 86:83–85PubMedCrossRefGoogle Scholar
  5. 5.
    Kim-Farley RJ, Rutherford G, Lichfield P, Hsu S-T, Orenstein WA, Schonberger LB, Bart KJ, Lui K-J, Lin C-C (1984) Outbreak of paralytic poliomyelitis, Taiwan. Lancet ii: 1322–1324CrossRefGoogle Scholar
  6. 6.
    World Health Organizaiton (1989) Expanded Programme on Immunization (EPI). Poliomyelitis in 1986,1987 and 1988, Part I. Wkly Epidem Rec 64: 273–279Google Scholar
  7. 7.
    Sutter RW, Patriarca PA, Brogan S, Malankar PG, Pallansch MA, Kew OM, Bass AG, Cochi SL, Alexander JP, Hall DB, Suleiman AJM, Al-Ghassany AAK, El-Bualy MS (1991) Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. Lancet 338: 715–720PubMedCrossRefGoogle Scholar
  8. 8.
    van Middelkoop A, van Wyk JE, Küstner HGV, Windsor I, Vinsen C, Schoub BD, Johnson S, McAnerney JM (1992) Poliomyelitis outbreak in Natal/KwaZulu, South Africa, 1987–1988. I. Epidemiology. Trans R Soc Trop Med Hyg 86:80–82PubMedCrossRefGoogle Scholar
  9. 9.
    Hovi T (1989) The outbreak of poliomyelitis in Finland in 1984–1985. Significance of antigenic variation of type 3 polioviruses and site-specificity of antibody responses in antipolio immunization. Adv Virus Res 37: 243–275PubMedCrossRefGoogle Scholar
  10. 10.
    World Health Organization (1984) Poliomyelitis outbreak in Israel. Wkly Epidem Rec 63:325–326Google Scholar
  11. 11.
    Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH (1991) Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 163: 1–6PubMedCrossRefGoogle Scholar
  12. 12.
    Department of National Health, South Africa (1990) The six vaccine-preventable diseases. Epidem Comments 17: 3–19Google Scholar
  13. 13.
    Tulchinsky T, Abed Y, Shaheen S, Toubassi N, Sever Y, Schoenbaum M, Handsher R (1989) A ten-year experience in control of poliomyelitis through a combination of live and killed vaccines in two developing areas. Am J Public Health 79: 1648–1652PubMedCrossRefGoogle Scholar
  14. 14.
    World Health Organization Expanded Programme on Immunization (1985) Global advisory group. Wkly Epidem Rec 60: 13–16Google Scholar
  15. 15.
    Schoub BD, Johnson S, McAnerney J, Gilbertson L, Klaassen KIM, Reinach SG (1988) Monovalent neonatal polio immunization -a strategy for the developing world. J Infect Dis 157: 836–839PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1993

Authors and Affiliations

  • B. D. Schoub
    • 1
  1. 1.National Institute for Virology and Department of VirologyUniversity of the WitwatersrandJohannesburgSouth Africa

Personalised recommendations